SCHEMBL13619841

SCHEMBL13619841

CCOC(=O)C(C(=O)OCC)C(=O)C(CCC(C)C)c1ccc(F)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 2/20 0.38
POLB P06746 2/20 0.36
MAPT P10636 4/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TSHR P16473 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPK1 P28482 1/20 0.34
KMO O15229 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13619854 0.88 MEN1 (0.37) POLBMAPTLMNAMEN1KMT2A
SCHEMBL12627685 0.86 POLB (0.34) APLNRPOLBMAPTLMNAMEN1
SCHEMBL12627671 0.83 EPHX2 (0.44) APLNRPOLBMAPTLMNAMEN1
SCHEMBL13619836 0.82 CXCR1 (0.37) APLNRPOLBMAPTLMNAMEN1
SCHEMBL12627632 0.81 ALDH1A1 (0.37) APLNRMEN1KMT2ACYP1A2CYP2C9
SCHEMBL13619603 0.80 MEN1 (0.52) LMNAMEN1KMT2ACYP1A2CYP2C9
SCHEMBL13619840 0.79 APLNR (0.44) APLNRNPSR1SMN1; SMN2MAPK1KMO
SCHEMBL12627677 0.78 ALDH1A1 (0.36) APLNRKMT2ACYP2C9NPSR1EPHX2
SCHEMBL16797554 0.77 APLNR (0.46) APLNRPOLBMAPTLMNAMEN1
SCHEMBL25265728 0.77 APLNR (0.43) APLNRPOLBMAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF APLNR 3713/4885POLB 540/4885MAPT 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.